Candriam S.C.A. Purchases 80,029 Shares of Olema Pharmaceuticals, Inc. $OLMA

Candriam S.C.A. increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 11.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 759,513 shares of the company’s stock after purchasing an additional 80,029 shares during the quarter. Candriam S.C.A. owned approximately 0.87% of Olema Pharmaceuticals worth $11,324,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Siren L.L.C. purchased a new stake in Olema Pharmaceuticals in the 4th quarter valued at about $82,518,000. Janus Henderson Group PLC boosted its stake in shares of Olema Pharmaceuticals by 87.1% in the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock worth $167,901,000 after buying an additional 3,124,345 shares during the last quarter. Cormorant Asset Management LP purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $68,750,000. RA Capital Management L.P. purchased a new position in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $65,000,000. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in shares of Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock valued at $212,716,000 after acquiring an additional 1,664,687 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

OLMA has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. JPMorgan Chase & Co. boosted their price objective on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. HC Wainwright restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Jefferies Financial Group started coverage on Olema Pharmaceuticals in a research report on Thursday, March 19th. They set a “buy” rating and a $40.00 target price for the company. Finally, Citigroup lifted their target price on Olema Pharmaceuticals from $60.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.10.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $11.91 on Monday. Olema Pharmaceuticals, Inc. has a 12 month low of $4.37 and a 12 month high of $36.26. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $12.17 and its 200 day moving average is $18.00. The stock has a market capitalization of $1.04 billion, a PE ratio of -5.90 and a beta of 2.00.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). Sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.